Who is sponsoring NCT01394211?

NCT01394211 is sponsored by University of Arizona.

What drugs are being tested in NCT01394211?

Interventions in NCT01394211: anastrozole, pazopanib hydrochloride, therapeutic conventional surgery.

What condition does NCT01394211 study?

NCT01394211 studies Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer.

Is NCT01394211 still recruiting?

NCT01394211 is currently terminated. Last updated 26 July 2018.

Are results published for NCT01394211?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-07-26 · How we verify

NCT01394211

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Terminated Phase 2 Results posted Last updated 26 July 2018

What this trial tests

Phase 2 trial testing anastrozole in Estrogen Receptor-positive Breast Cancer in 2 participants. Terminated before completion.

Timeline

13 July 2011

Primary endpoint
12 April 2012

12 April 2012

Quick facts

Lead sponsor	University of Arizona
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	13 July 2011
Primary completion	12 April 2012
Estimated completion	12 April 2012
Sites	1 location across United States

Drugs / interventions tested

anastrozole (anastrozole) — full drug profile →
pazopanib hydrochloride — full drug profile →
therapeutic conventional surgery

Conditions studied

Estrogen Receptor-positive Breast Cancer — all drugs for Estrogen Receptor-positive Breast Cancer →
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast — all drugs for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast →
Male Breast Cancer — all drugs for Male Breast Cancer →
Recurrent Breast Cancer — all drugs for Recurrent Breast Cancer →

Sponsor

University of Arizona

Who can join

18 and older, any sex, with Estrogen Receptor-positive Breast Cancer or Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride and anastrozole together before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of anastrozole

Trials testing the same drug.

NCT02942355 — Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer · Phase 2 · active not recruiting
NCT02269670 — Phase II Study of Everolimus Beyond Progression · Phase 2 · terminated
NCT01953588 — Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery · Phase 3 · active not recruiting
NCT01597193 — Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer · Phase 1 · completed
NCT00893061 — Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer · Phase 3 · completed

Other recruiting trials for Estrogen Receptor-positive Breast Cancer

Currently open trials in the same condition.

NCT06439693 — The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · Phase 2 · recruiting
NCT04597580 — Personalised Disease Monitoring in Metastatic Breast Cancer · active not recruiting
NCT02957968 — Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca · Phase 2 · active not recruiting
NCT01953588 — Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery · Phase 3 · active not recruiting

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01394211 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 26 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01394211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing